World of DTC Marketing

JUNE 9, 2025

For decades, pharma companies have relied on direct-to-consumer (DTC) television ads to build awareness and drive demand for prescription drugs. However, as the healthcare landscape continues to evolve—and trust in institutions declines—it’s time for the industry to confront a hard truth: DTC TV ads are no longer as effective as they once were. They may be increasingly out of step with how patients make healthcare decisions today.

Doctor 206

Doctor Doctors Drugs Marketing 206

Scienmag

JUNE 7, 2025

In an era where precision medicine is rapidly transforming pediatric healthcare, a groundbreaking nationwide study has emerged, shedding light on the utility of biological treatments in children suffering from eosinophilic esophagitis (EoE). Published in Pediatric Research in 2025, this comprehensive investigation led by Soudant, Lejeune, Aumar, and their colleagues delves into an intricate analysis of the clinical efficacy, safety, and long-term outcomes associated with biologic therapeutics ap

Medicine 78

Medicine Immune Response Research Nurses 78

ACRP blog

JUNE 13, 2025

The U.S. Food and Drug Administration’s (FDA’s) recent launch of an agency-wide large language model–powered artificial intelligence (AI) tool known Elsa and ongoing efforts to have another AI tool known as CDRH-GPT in place for speeding up reviews and approvals of medical devices by the end of June have attracted their share of both supporters and detractors.

Clinical Trials 93

Clinical Trials Clinical Trials Trials Clinical Research 93

pharmaphorum

JUNE 10, 2025

Discover how statistical methodologies are transforming drug development by leveraging real-world evidence (RWE) to improve decision-making and outcomes. Explore the impact and benefits of utilising RWE in pharmaceutical research.

Development 52

Development Drugs Research 52

Speaker: Brian Richardson, Brian Richardson, Founder and CEO of Richardson Consulting Group

Let’s face it—most ethics and compliance training programs aren’t winning awards for engagement. But that doesn’t mean they can’t be effective, captivating, and maybe even enjoyable! Join learning design expert Brian Richardson for a dynamic session on how to breathe new life into your ethics and compliance training. We'll explore innovative strategies to bring traditionally dry topics to life, making them resonate with learners and drive tangible change.

Compliance

Rethinking Clinical Trials

JUNE 12, 2025

A new chapter of the Living Textbook of Pragmatic Clinical Trials describes regulatory requirements for informed consent, waivers and alterations of consent, mechanisms for notification, and research participants’ perspectives on a variety of approaches to consent and notification—all with a focus on special considerations for pragmatic clinical trials.

Trials 100

Trials Clinical Trials Clinical Trials Regulation 100

Scienmag

JUNE 10, 2025

Cancer remains a formidable adversary in global health, affecting millions annually and presenting persistent challenges to effective treatment. Despite significant advances through precision medicine and targeted therapies that have reshaped oncology, the issues of drug resistance and disease recurrence continue to plague many patients. A seminal review recently published in Genes & Diseases sheds light on the revolutionary potential of patient-derived xenograft (PDX) models as a transforma

Research 59

Research Clinical Trials Clinical Trials Gene Editing 59

NY Times

JUNE 11, 2025

Skip to content Skip to site index Today’s Paper Opinion | It’s Code Red for Vaccines [link] Share full article 205 205 Advertisement SKIP ADVERTISEMENT You have a preview view of this article while we are checking your access. When we have confirmed access, the full article content will load. Opinion Supported by SKIP ADVERTISEMENT Guest Essay It’s Code Red for Vaccines June 11, 2025, 5:03 a.m.

Vaccine 132

Vaccine Vaccination Licensing Licensing 132

Rethinking Clinical Trials

JUNE 10, 2025

                            Speaker Jonathan D. Casey, MD, MSc Assistant Professor, Pulmonary & Critical Care, Vanderbilt University Co-PI, Vanderbilt Trial Innovation Center Director, Coordinating Center, Pragmatic Critical Care Research Group Slides Keywords Randomization; Randomized Clinical Trial; REDCap; Innovation Key Points In a traditional randomized trial, trial procedures—including eligibility criteria, group allocation, intervention, and sample size—are

Trials 113

Trials Clinical Trials Clinical Trials Research 113

Scienmag

JUNE 10, 2025

In the delicate and high-stakes world of neonatal medicine, the fight against lung inflammation in preterm infants has taken a promising turn with recent advances in steroid therapy. Researchers have begun to delve deep into the nuanced effects of two potent corticosteroids, budesonide and hydrocortisone, revealing their distinct influences on the vulnerable lungs and developing brains of ventilated preterm lambs—an animal model that closely replicates human premature infants.

Drug Delivery Systems 59

Drug Delivery Systems Gene Expression Drug Delivery Medicine 59

The Pharma Data

JUNE 12, 2025

Bleximenib Shows Promise in AML When Combined with Venetoclax and Azacitidine, According to Johnson & Johnson’s Phase 1b Data Presented at EHA 2025 Johnson & Johnson today presented new and promising Phase 1b data demonstrating strong antileukemic activity and a favorable safety profile for bleximenib (JNJ-75276617) in combination with venetoclax (VEN) and azacitidine (AZA) in patients with acute myeloid leukemia (AML) who harbor KMT2A gene rearrangements (KMT2Ar) or NPM1 mutations (NPM1

Gene 40

Gene Trials Clinical Development Development 40

Advertisement

Enhancing Transparency & Efficiency Throughout the Trial Lifecycle for AI Readiness

Trials

Pharma Times

JUNE 11, 2025

Subscribe Advertise About us Follow Follow Follow Follow GO Magazine PharmaTimes Magazine Archive Web Exclusives News Competitions Appointments Business Insights Webinars Thought Leadership Jobs Argenx presents new efgartigimod data at EULAR 2025 by John Pinching | 11th Jun 2025 | News Rheumatology studies show promising results for Sjogren’s disease Argenx has presented positive phase 2 results for efgartigimod in myositis and Sjogren’s disease at EULAR 2025.

Sales 119

Sales Clinical Research Clinical Development Research 119

ACRP blog

JUNE 11, 2025

In the midst of this Pride Month, current politically motivated headwinds may be driving some of the terminology related to inclusive research underground, but the scientific rationale for inclusive studies is here to stay because “smart science is smart business,” says a presenter from ACRP 2025. Addressing issues surrounding sexual gender minority (SGM) health inequities and the importance of collecting sexual orientation and gender identity (SOGI) data during clinical trials, Meghan McKenzi

Clinical Trials 59

Clinical Trials Clinical Trials Packaging Packaging 59

Scienmag

JUNE 12, 2025

For decades, the exploration of the human brain through noninvasive techniques has been a frontier of neuroscience, with researchers pursuing the unseen depths of this complex organ. The traditional method utilized in this quest is known as functional near-infrared spectroscopy, or fNIRS. This optical imaging approach has offered a window into brain activity by measuring how light is absorbed by blood flowing through the brain, allowing scientists to infer areas of activity and engagement.

Scientist 59

Scientist Research Engineer Development 59

The Pharma Data

JUNE 9, 2025

WuXi Biologics and VISEN Pharmaceuticals Expand Partnership to Localize Production of Lonapegsomatropin in China WuXi Biologics ,a global leader in Contract Research, Development, and Manufacturing Organization (CRDMO) services, and VISEN Pharmaceuticals (HKEX: 2561), a clinical-stage biopharmaceutical company dedicated to advancing endocrine disease treatments, have announced the formal launch of the technology transfer process for the commercial production of lonapegsomatropin.

Hormones 40

Hormones Manufacturing Production Development 40

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

Clinical Trials

Imperical Blog

JUNE 10, 2025

Is outsourcing clinical trial services a smart strategy or a risky gamble? The answer depends on how you approach it. This topic was particularly highlighted for me during the Outsourcing in Clinical Trials East Coast conference, which took place at the Valley Forge Casino Resort… The post Outsourcing Clinical Trial Services: Reduce Risk & Maximize Reward appeared first on Imperial Clinical Research Services Blog.

Clinical Trials 93

Clinical Trials Clinical Trials Trials Clinical Research 93

XTalks

JUNE 11, 2025

The global biologics market is experiencing significant growth, projected to reach $732.4 billion by 2030, up from $421.1 billion in 2023, with a compound annual growth rate (CAGR) of 8.2%. This surge underscores the increasing demand for efficient, cost-effective manufacturing processes, particularly in early-phase clinical programs. As biologics developers accelerate timelines for first-in-human (FIH) clinical programs, the need for streamlined, flexible downstream processes is intensifying.

Protein 92

Protein Manufacturing Antibody Production 92

Scienmag

JUNE 13, 2025

Singapore – Scientists from the A*STAR Genome Institute of Singapore (A*STAR GIS) have developed a new artificial intelligence (AI)-based method called “Fragle” that makes tracking cancer easier and faster using blood tests. Requiring only a small blood sample, this method analyses the size of DNA fragments in the blood to reveal distinct patterns that differentiate cancer DNA from healthy DNA, helping doctors track cancer treatment response more accurately and frequently.

DNA 59

DNA Genomics Genome Genetics 59

The Pharma Data

JUNE 11, 2025

FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications, Offering Greater Convenience for Patients with B-cell Cancers BeOne Medicines Ltd. a global oncology-focused biopharmaceutical company, has received a significant regulatory milestone from the U.S. Food and Drug Administration (FDA). The agency has officially approved a new tablet formulation of BRUKINSA® (zanubrutinib) for all five of its previously approved indications.

FDA Approval 40

FDA Approval Bioequivalency Marketing Medicine 40

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Medicine

Pharma Times

JUNE 11, 2025

Subscribe Advertise About us Follow Follow Follow Follow GO Magazine PharmaTimes Magazine Archive Web Exclusives News Competitions Appointments Business Insights Webinars Thought Leadership Jobs Bimekizumab shows lasting efficacy at EULAR 2025 by John Pinching | 11th Jun 2025 | News Three-year data highlights inflammation control in psoriatic arthritis UCB has announced new three-year data from phase 3 trials and their open-label extensions investigating BIMZELX (bimekizumab) in psoriatic arthri

Sales 81

Sales Clinical Research Trials Research 81

STAT News

JUNE 11, 2025

Europe’s comparatively cautious approach to food additives is the envy of health secretary Robert F. Kennedy Jr. and the Make America Healthy Again movement. A Texas bill now before Gov. Greg Abbott aims to help close the gap by slapping warning labels on foods that contain any of 44 additives and dyes. Abbott has not said whether he intends to sign Senate Bill 25 into law.

Containment 118

Containment Scientist Research 118

Scienmag

JUNE 10, 2025

In a groundbreaking development that promises to accelerate drug discovery and pharmaceutical research, Insilico Medicine, a leading clinical-stage biotechnology company harnessing generative artificial intelligence, has announced the launch of its latest foundation model, Nach01, on Amazon Web Services (AWS). This significant release, available through the AWS Marketplace, marks a pivotal advancement in the integration of advanced AI technologies within the drug design domain.

Medicine 75

Medicine Drugs Research Development 75

The Pharma Data

JUNE 11, 2025

Ionis Begins Pivotal Phase 3 REVEAL Study of ION582 in Angelman Syndrome, Dosing First Patient in Global Trial Ionis Pharmaceuticals , Inc. (Nasdaq: IONS) has announced the dosing of the first patient in the Phase 3 REVEAL clinical trial, marking a significant milestone in the development of ION582, an investigational therapy for Angelman syndrome (AS).

Trials 40

Trials Gene Genetics Gene Expression 40

Speaker: Amie Phillips Pablo, VP, Corporate Compliance & Privacy Officer at Novo Nordisk

In today’s complex healthcare environment, navigating third-party relationships has become even more challenging—whether it’s vendor relationships, employee activities, or patient-facing interactions. Left unmanaged, these conflicts can compromise trust, regulatory compliance, and even organizational reputation. So, how can healthcare teams stay ahead?

Compliance

XTalks

JUNE 10, 2025

Otsuka Pharmaceutical has announced promising interim Phase III results for sibeprenlimab in the treatment of the rare and progressive autoimmune kidney disease immunoglobulin A nephropathy (IgAN). The data, presented from the VISIONARY trial, demonstrated a statistically significant and clinically meaningful reduction in proteinuria — a key indicator of disease progression.

Trials 52

Trials Clinical Trials Clinical Trials Antibody 52

STAT News

JUNE 11, 2025

In December 2023, a groundbreaking announcement grabbed headlines : After years of anticipation, the Food and Drug Administration approved the first gene therapies for treating sickle cell disease, offering hope of eliminating life-altering symptoms. News at the time also featured the treatment’s prohibitive cost — between $2 and $3 million per person.

Gene Therapy 118

Gene Therapy Gene Drugs 118

Scienmag

JUNE 10, 2025

Breast cancer continues to stand as one of the most formidable health challenges facing women globally. Despite advances in detection and treatment, the disease’s complexity demands deeper understanding, especially concerning the molecular and metabolic changes underpinning tumor growth and resistance. Recent scientific inquiry has turned a spotlight onto the metabolic reprogramming of breast cancer cells, uncovering how alterations in glucose, lipid, and amino acid metabolism collectively fuel

Gene 75

Gene Medicine Hormones Research 75

The Pharma Data

JUNE 9, 2025

Ascendis Pharma Reports Promising Week 26 Results from COACH Trial: TransCon hGH Enhances TransCon CNP Benefits in Children with Achondroplasia Ascendis Pharma A/S, a global biopharmaceutical company focused on developing innovative therapies for rare diseases and endocrine disorders, has announced interim results from the Week 26 analysis of its ongoing Phase 2 COACH trial.

Trials 40

Trials Hormones Development Genetics 40

Advertisement

Download this comprehensive guide to AI and ML in the R&D Laboratory Setting.

Life Science

Pharmaceutical Technology

JUNE 13, 2025

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

Vaccine 219

Vaccine Vaccination Development Clinical Trials 219

BioTech 365

JUNE 8, 2025

Azafaros to Present at BIO International Convention 2025 Following Successful €132M Series B Financing Azafaros to Present at BIO International Convention 2025 Following Successful €132M Series B Financing LEIDEN, Netherlands–(BUSINESS WIRE)–#Adults–Azafaros, a clinical-stage biotechnology company developing novel therapies for rare … Continue reading →

Development 52

Development 52

Scienmag

JUNE 13, 2025

image: Dr. Ravindra Uppaluri, director of Head and Neck Surgical Oncology at Dana-Farber and Brigham and Women’s Hospital view more Credit: Courtesy of Dana-Farber Cancer Institute BOSTON, June 13, 2025 — Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an

FDA Approval 59

FDA Approval Research Clinical Trials Clinical Trials 59

The Pharma Data

JUNE 12, 2025

EULAR 2025: Rilzabrutinib Shows Promise in IgG4-Related Disease — Reduction in Flares and Disease Activity Rilzabrutinib , a Bruton’s tyrosine kinase (BTK) inhibitor currently in clinical development, demonstrated a significant and sustained reduction in disease flares and key disease activity markers in patients with IgG4-related disease (IgG4-RD) , according to new data presented at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress in Barcelona, Spain (June 11–14).

Clinical Development 40

Clinical Development Medicine Development Drugs 40

Advertisement

Clinical Supply